Marga Nijenhuis

3.3k total citations · 2 hit papers
29 papers, 2.1k citations indexed

About

Marga Nijenhuis is a scholar working on Molecular Biology, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Marga Nijenhuis has authored 29 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 11 papers in Pharmacology and 9 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Marga Nijenhuis's work include Pharmacogenetics and Drug Metabolism (11 papers), RNA Interference and Gene Delivery (6 papers) and Pharmaceutical studies and practices (5 papers). Marga Nijenhuis is often cited by papers focused on Pharmacogenetics and Drug Metabolism (11 papers), RNA Interference and Gene Delivery (6 papers) and Pharmaceutical studies and practices (5 papers). Marga Nijenhuis collaborates with scholars based in Netherlands, United Kingdom and United States. Marga Nijenhuis's co-authors include Vera H.M. Deneer, Jesse J. Swen, Henk‐Jan Guchelaar, Gerard A. Rongen, Ron H. N. van Schaik, Jan van der Weide, Bob Wilffert, Daan J. Touw, Anthonius de Boer and Anke H. Maitland‐van der Zee and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Cell Biology and The Journal of Immunology.

In The Last Decade

Marga Nijenhuis

27 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pharmacogenetics: From Bench to Byte— An Update of Guidelines

2011 747 citations Jesse J. Swen, Marga Nijenhuis et al. profile →
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics

2023 71 citations Marga Nijenhuis, Bianca Soree et al. European Journal of Human Genetics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marga Nijenhuis Netherlands	21	915	650	462	420	382	29	2.1k
Ann M. Moyer United States	24	680 0.7×	541 0.8×	311 0.7×	429 1.0×	219 0.6×	109	2.1k
Victoria M. Pratt United States	33	1.1k 1.3×	952 1.5×	381 0.8×	656 1.6×	149 0.4×	106	3.3k
Ryan Owen United States	17	293 0.3×	719 1.1×	535 1.2×	280 0.7×	135 0.4×	35	2.4k
Neil Miller United States	28	643 0.7×	984 1.5×	277 0.6×	385 0.9×	163 0.4×	60	2.9k
Patrick Caron Canada	30	595 0.7×	778 1.2×	770 1.7×	312 0.7×	91 0.2×	80	2.4k
Monette Cotreau United States	19	312 0.3×	460 0.7×	359 0.8×	130 0.3×	92 0.2×	52	1.8k
Paola Borgiani Italy	31	238 0.3×	846 1.3×	173 0.4×	113 0.3×	556 1.5×	137	2.6k
Donna J. Buckley United States	26	218 0.2×	713 1.1×	548 1.2×	197 0.5×	204 0.5×	58	1.8k
Pallav Bhatnagar United States	14	453 0.5×	207 0.3×	178 0.4×	135 0.3×	102 0.3×	28	1.2k

Countries citing papers authored by Marga Nijenhuis

Since Specialization

Citations

This map shows the geographic impact of Marga Nijenhuis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marga Nijenhuis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marga Nijenhuis more than expected).

Fields of papers citing papers by Marga Nijenhuis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marga Nijenhuis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marga Nijenhuis. The network helps show where Marga Nijenhuis may publish in the future.

Co-authorship network of co-authors of Marga Nijenhuis

This figure shows the co-authorship network connecting the top 25 collaborators of Marga Nijenhuis. A scholar is included among the top collaborators of Marga Nijenhuis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marga Nijenhuis. Marga Nijenhuis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nijenhuis, Marga, et al.. (2026). Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between CYP2D6 and CYP2C19 and tricyclic antidepressants. European Journal of Human Genetics. 34(3). 379–386.

Coenen, Marieke J. H., Marga Nijenhuis, Bianca Soree, et al.. (2025). Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between TPMT/NUDT15 and thiopurines. European Journal of Human Genetics. 34(1). 152–160.

Nijenhuis, Marga, Bianca Soree, Nienke J. de Boer‐Veger, et al.. (2024). Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between SLCO1B1 and statins and CYP2C9 and sulfonylureas. European Journal of Human Genetics. 33(4). 413–420. 2 indexed citations

Manson, Lisanne E. N., Marga Nijenhuis, Bianca Soree, et al.. (2024). Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugs. European Journal of Human Genetics. 32(8). 903–911. 8 indexed citations

Nijenhuis, Marga, Bianca Soree, Nienke J. de Boer‐Veger, et al.. (2024). Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP2C19 and non-SSRI/non-TCA antidepressants. European Journal of Human Genetics. 32(11). 1371–1377. 6 indexed citations

Nijenhuis, Marga, Bianca Soree, Nienke J. de Boer‐Veger, et al.. (2023). Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics. European Journal of Human Genetics. 32(3). 278–285. 71 indexed citations breakdown →

Nijenhuis, Marga, Bianca Soree, Nienke J. de Boer‐Veger, et al.. (2022). Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction of CYP2D6 and COMT with atomoxetine and methylphenidate. European Journal of Human Genetics. 31(12). 1364–1370. 16 indexed citations

Nijenhuis, Marga, Bianca Soree, Nienke J. de Boer‐Veger, et al.. (2022). Dutch pharmacogenetics working group guideline for the gene-drug interaction of ABCG2, HLA-B and Allopurinol, and MTHFR, folic acid and methotrexate. European Journal of Human Genetics. 32(2). 155–162. 20 indexed citations

Matić, Maja, Marga Nijenhuis, Bianca Soree, et al.. (2021). Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). European Journal of Human Genetics. 30(10). 1105–1113. 31 indexed citations

10.

Brouwer, J., Marga Nijenhuis, Bianca Soree, et al.. (2021). Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs. European Journal of Human Genetics. 30(10). 1114–1120. 78 indexed citations

11.

Abdullah-Koolmees, H., et al.. (2021). Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines. Frontiers in Pharmacology. 11. 595219–595219. 122 indexed citations

12.

Lunenburg, Carin A.T.C., Cathelijne H. van der Wouden, Marga Nijenhuis, et al.. (2019). Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines. European Journal of Human Genetics. 28(4). 508–517. 153 indexed citations

13.

Bree, F.M. de, et al.. (2003). The Hormone Domain of the Vasopressin Prohormone is Required for the Correct Prohormone Trafficking Through the Secretory Pathway. Journal of Neuroendocrinology. 15(12). 1156–1163. 23 indexed citations

14.

Nijenhuis, Marga, et al.. (2000). A diabetes insipidus vasopressin prohormone altered outside the central core of neurophysin accumulates in the endoplasmic reticulum. Molecular and Cellular Endocrinology. 167(1-2). 55–67. 19 indexed citations

15.

Nijenhuis, Marga, et al.. (1999). Mutations in the Vasopressin Prohormone Involved in Diabetes Insipidus Impair Endoplasmic Reticulum Export but Not Sorting. Journal of Biological Chemistry. 274(30). 21200–21208. 46 indexed citations

16.

Nijenhuis, Marga, S. Schmitt, Elena Armandola, et al.. (1996). Identification of a contact region for peptide on the TAP1 chain of the transporter associated with antigen processing. The Journal of Immunology. 156(6). 2186–2195. 66 indexed citations

17.

Armandola, Elena, Frank Momburg, Marga Nijenhuis, et al.. (1996). A point mutation in the human transporter associated with antigen processing (TAP2) alters the peptide transport specificity. European Journal of Immunology. 26(8). 1748–1755. 71 indexed citations

18.

Obst, Reinhard, Elena Armandola, Marga Nijenhuis, Frank Momburg, & Günter J. Hämmerling. (1995). TAP polymorphism does not influence transport of peptide variants in mice and humans. European Journal of Immunology. 25(8). 2170–2176. 71 indexed citations

19.

Nijenhuis, Marga, Jero Calafat, Hans Janssen, et al.. (1994). Targeting major histocompatibility complex class II molecules to the cell surface by invariant chain allows antigen presentation upon recycling. European Journal of Immunology. 24(4). 873–883. 20 indexed citations

20.

Nijenhuis, Marga & Jacques Neefjes. (1994). Early events in the assembly of major histocompatibility complex class II heterotrimers from their free subunits. European Journal of Immunology. 24(1). 247–256. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact